SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-23-022802
Filing Date
2023-05-18
Accepted
2023-05-17 18:01:31
Documents
13
Period of Report
2023-05-17
Items
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K sndx-20230517.htm   iXBRL 8-K 83637
2 EX-3.1 sndx-ex3_1.htm EX-3.1 17801
  Complete submission text file 0000950170-23-022802.txt   228511

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT sndx-20230517_pre.xml EX-101.PRE 10616
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT sndx-20230517_lab.xml EX-101.LAB 14461
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT sndx-20230517.xsd EX-101.SCH 2463
7 EXTRACTED XBRL INSTANCE DOCUMENT sndx-20230517_htm.xml XML 5050
Mailing Address 35 GATEHOUSE DRIVE BUILDING D, FLOOR 3 WALTHAM MA 02451
Business Address 35 GATEHOUSE DRIVE BUILDING D, FLOOR 3 WALTHAM MA 02451 781-419-1400
Syndax Pharmaceuticals Inc (Filer) CIK: 0001395937 (see all company filings)

IRS No.: 320162505 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37708 | Film No.: 23933147
SIC: 2834 Pharmaceutical Preparations